TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Innovent Biologics ( (HK:1801) ) has provided an announcement.
Innovent Biologics has announced that its new drug, PECONDLE® (picankibart injection), has received approval from China’s National Medical Products Administration for treating moderate-to-severe plaque psoriasis. This approval marks the first domestically developed IL-23p19 monoclonal antibody in China, offering significant benefits such as improved skin clearance and quality of life for patients. The drug’s approval is based on positive results from a Phase 3 clinical study, positioning Innovent as a key player in the evolving psoriasis treatment landscape, which is shifting towards precision therapies.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$89.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies, particularly in the field of autoimmunity. The company is known for its pipeline of biologics and small molecule-targeted drugs, with a market focus on precision therapies for conditions like psoriasis.
Average Trading Volume: 17,046,198
Technical Sentiment Signal: Buy
Current Market Cap: HK$162.6B
For an in-depth examination of 1801 stock, go to TipRanks’ Overview page.